Digestive Health Newsletter

IBD and Your Lifestyle

Ellen J. Scherl, MD

Volume 6, 
October 01, 2006

by Ellen J. Scherl, MD

Ellen Scherl Ellen J. Scherl, MD, is Director at the Jill Roberts Center for Inflammatory Bowel Disease at New York-Presbyterian/Weill Cornell Medical Center, Jill Roberts Associate Professor for Inflammatory Bowel Disease, and Associate Professor of Medicine, Division of Gastroenterology and Hepatology, Weill Medical College of Cornell University, specializing in the medical treatment of inflammatory bowel disease (IBD). She is a principal investigator and participates in clinical trials involving treatments for IBD and has contributed numerous scholarly articles, reviews, and commentaries to the scientific literature of IBD. Dr. Scherl is a member and has served in a leadership capacity of numerous professional societies related to gastroenterology and IBD. She is certified in Internal Medicine and Gastroenterology by the American Board of Internal Medicine. Dr. Scherl was the recipient of the Crohn's and Colitis Foundation's Woman of Distinction Award in 1996.

Table of Contents

Introduction

In addition to taking your medication and watching your diet, there are many other ways to manage your wellness that can influence your inflammatory bowel disease (IBD). This newsletter will focus on lifestyle choices you can make to help you control IBD symptoms, limit its impact on your activities, and lengthen the time between flare-ups. Specific sections include exercise, stress, smoking, travel, and sexuality and reproductive issues.

Exercise

While exercise cannot control IBD and has not been systematically studied in IBD patients over long periods of time, staying fit will help you respond better to flare-ups. Even though you may not always feel like exercising, regular exercise will increase your energy levels and decrease the stress and depression often associated with IBD1. Exercising doesn't have to be strenuous and doesn't necessarily mean regular trips to the gym. You can increase your physical activity by walking or using exercise videos in the privacy of your home. If you have been sedentary for awhile, start slowly and gradually increase the intensity and duration of your activity.

Aerobic exercise, like walking, hiking, jogging, biking, swimming, and skating, can help counter some of the side effects of IBD. For example, it can reverse muscle weakness and wasting and also prevent calcium and protein loss2. While many people with IBD enjoy vigorous exercise, some find that aerobic exercises involving bouncy movement, like running, increases cramping, nausea, vomiting, and diarrhea. For these individuals, walking, swimming, skating, or cross-country skiing may be more tolerable. To prevent injury to your joints and muscles, start with a 5- to 10-minute low-intensity warm-up period. Likewise, ending your exercise session with a 5- to 10-minute cool-down period will allow your breathing, heart rate, and blood pressure to gradually return to resting levels.

If you are taking glucocorticoids, resistance training may slow or reverse the progression of muscle and bone loss associated with those medications3. Such training typically involves the use of free weights, weight machines, or elastic bands. It is important to get proper instruction in the use of exercise equipment to avoid injury. When working out in a gym, avoid touching your face and remember to wash your hands carefully before heading home, especially if you are taking immunosuppressive medication. Weights and other equipment can be sources of disease-causing germs.

Remember that IBD increases your risk of dehydration, so be sure to drink plenty of fluids before, during, and after exercise, even if you don't feel thirsty. Water is a great choice, or you may want to try commercial sport drinks that are rich in sodium and potassium. It may help to avoid eating solid foods for several hours before aerobic activity.

Check with your doctor before beginning any exercise program. Although most types of physical activity are fine for people with IBD, your physician will know whether any special considerations apply to you based on your specific medical history. For example, if you have been on corticosteroids for a long time, running may place too much stress on your bones at the outset and you may need to begin your exercise program with a lower impact activity.

Back to Top

Stress

Although there is no evidence that stress causes IBD, IBD can certainly cause stress! Stress is a common side effect of any chronic illness with symptoms that come and go throughout life. When you are feeling stressed, your normal digestive process changes4. Your stomach empties more slowly and secretes more acids. Stress can also speed up or slow down the movement of food through your intestines and cause changes in your intestinal lining. Thus, stress can aggravate your symptoms, resulting in a cycle of flare-ups that may include increased abdominal pain or diarrhea.

Relaxation strategies can help you control stress and better manage your disease5. This can be as simple as setting aside at least 20 minutes each day for a calming activity, like reading, listening to music, soaking in the tub, playing a computer game, or working on a crossword puzzle. The main thing is to pick an activity that you find relaxing. Many people find that regular tai chi, yoga, or meditation helps to relieve stress. Look for classes in your community or books and tapes that teach you how to practice at home. Biofeedback is a formal stress reduction technique that helps you achieve a relaxed state by reducing muscle tension and slowing your heart rate using a feedback machine. It is usually taught in clinics and medical centers. With practice, you can learn to achieve a relaxed state without using the machine.

If you are experiencing significant, ongoing stress, you may find it helpful to talk to a mental health professional. Some patients benefit from antianxiety or antidepressant medications. Your physician can refer you to the appropriate mental health professional whether that's a social worker, psychologist, psychotherapist, or psychiatrist. It is important to choose a mental health professional who is familiar with IBD and understands some of the psychological challenges involved.

Back to Top

Smoking

People who smoke or have smoked in the past have a higher risk of developing Crohn's disease than do nonsmokers. If you have Crohn's disease, smoking can increase the number of flare-ups you experience, as well as your need for surgery and aggressive treatment.6

Paradoxically, the risk of developing ulcerative colitis is higher in nonsmokers and former smokers than in current smokers, and the onset of ulcerative colitis sometimes appears to coincide with smoking cessation.7,8 Researchers think that the nicotine in cigarettes may have a protective effect on ulcerative colitis. More specifically, nicotine may affect the muscle that lines the large intestine, slowing down the movement of waste. Smoking cessation is often associated with a flare of ulcerative colitis. Nicotine is also the substance in cigarettes that makes them highly addictive, which is why many people who smoke have trouble quitting despite the serious health risks, like cancer and heart and lung disease. That is why smoking is never a good idea, even if you have ulcerative colitis.

Several studies found that nicotine patches, which smokers wear to help them quit, helped decrease ulcerative colitis symptoms during a flare-up. However, patients using the patches commonly reported negative side effects, such as nausea, light-headedness, and headache.9,10 Unfortunately, nicotine patches do not seem to help patients with ulcerative colitis stay in remission.11

Back to Top

Travel

Traveling with a chronic disease may seem daunting, but there is no reason to avoid a vacation or business trip just because you have IBD if your symptoms are under reasonable control and you feel well enough to travel. By planning ahead and taking some precautions, you can leave town or even the country and stay healthy and comfortable. Remember to take your medications along with you on your trip.

Before You Travel

Discuss your travel plans with your physician and be sure to take along his/her phone number. Your physician may also be able to provide you with the name and phone number of a doctor in the area you'll be visiting, as well as a letter describing your medical condition should you need medical care while you are away. You may also want to ask for written care plans to follow in case of a mild, moderate, or severe relapse.

Also check in with your pharmacist before you leave town. Be sure to bring more than enough prescription and over-the-counter medication for your trip. The same is true for any supplies you may need — always pack extra. This will give you peace of mind if your return trip is delayed for any reason. It is also a good idea to bring along copies of all prescriptions, including generic names and foreign brand names if you are traveling to another country.

Finally, call your health insurance company to confirm your coverage while you travel. If you are not covered when traveling, look into getting travel insurance or short-term insurance. Your insurance agent may be able to give you a referral or your credit card company may offer health insurance while you travel.

Traveling by Car

If you are traveling a long distance by car, contact local tourist boards or an auto club to find rest stops on your route. If there are no rest stops along the highway, note the locations of busy intersections where you are most likely to find a restaurant or grocery store with bathroom facilities. If you are driving through remote rural areas, you may want to consider keeping a portable toilet in the trunk of your car.

Traveling by Plane

If you are traveling by plane, make reservations in advance and request an aisle seat close to the bathroom. If a meal will be served on your flight, ask about the availability of special meals if you have any dietary restrictions. Always pack your medication (in its original container) and other necessary supplies in your carry-on bag, so you have it with you at all times. Due to enhanced security measures most liquids, gels, lotions and other items of similar consistency will not be permitted in carry-on baggage. However, prescription medicine with a name that matches the passenger's ticket, up to 5 oz. of liquid or gel and up to 4 oz. of non-prescription liquid medications, are permitted. Additional amounts of liquid medications, in excess of the permissible amount, should be packed in checked baggage. You may also want to include a change of clothes, wet wipes, and any other things you might need in an emergency or if a bathroom is not well-stocked. If you find yourself needing the bathroom urgently and there's a line, explain your situation to a flight attendant and request assistance.

Avoiding Travelers' Diarrhea

Everyone is at increased risk for gastrointestinal problems when traveling to less developed countries where there may be inadequate sanitation. Such problems are typically due to intestinal infection caused by bacteria, parasites, or viruses in contaminated food or water. If you have IBD, you need to be especially careful about the food you eat and the water you drink.

Here are some tips to keep you healthy:

Back to Top

Sexuality And Reproductive Issues

Sexuality

Even though IBD is a digestive disease, its symptoms and treatment can have an impact on your sexuality. Side effects can occasionally be a frustrating experience for both you and your partner. Remember that healthy adult relationships are more than just sexual gratification. Finding a way to work through this challenge can bring you closer together as a couple.

Fertility

Neither ulcerative colitis nor inactive Crohn's disease will affect your fertility. However, both men and women with active Crohn's disease may experience a slight decrease in fertility. This is most commonly due to malnutrition and can be reversed with a return to a healthy nutrition status.

Most drugs used to treat IBD have no effect on fertility. One exception is sulfasalazine, which causes reduced and abnormally shaped sperm in men.14 Fertility returns to normal within two months of discontinuing the drug.

As described above, when surgery for ulcerative colitis involves removing the rectum or anus, there is a rare chance that reproductive problems may result. For example, surgery in a woman's pelvic area can lead to scarring and adhesions. This could affect the fallopian tubes and make it difficult to conceive. Men who have their rectum removed face a very slight risk of impotency and problems with ejaculation.15

Pregnancy

IBD is unlikely to have any effect on your pregnancy or fetus if your disease is in remission when you conceive. However, if your disease is active at conception, it is likely to remain active or worsen during your pregnancy. With ulcerative colitis, the worsening usually occurs during the first trimester; with Crohn's disease, the worsening usually occurs at the end of the third trimester and after delivery. If ulcerative colitis or Crohn's disease becomes active while you are pregnant, you will have a slightly increased risk of miscarriage or premature birth. Therefore, it is important to treat flare-ups quickly. In general, it has been found that treating a flare-up with medication carries less risk than continuing a pregnancy without treatment, however some drugs (for example metronidazole) should be avoided during pregnancy. Methotrexate is contraindicated.16 Be sure to discuss your medications with your physician before you get pregnant.

Back to Top

Summary

Living with IBD may feel overwhelming at times. However, living well by taking your medication as prescribed, watching your diet to avoid aggravating foods and ensure solid nutrition, getting regular aerobic exercise, taking steps to manage your stress, and planning for challenging aspects of life with IBD such as travel puts you in charge of your disease and your life. No one can promise you a life without flare-ups. No one can assure you that you will never need surgery. But you can take charge of the rest of your life and be healthier and stronger so that you are not laid so low if and when these events do occur. You have a long life ahead of you. IBD is a part of your life and must be taken into consideration and managed through sound medical care and rational adjustments to your lifestyle. If you take care of your IBD, it will take care of you.

CCFAThis information has been reviewed and approved by CCFA's National Scientific Advisory Committee.


  1. Loudon CP, Corroll V, Butcher J, et al. The effects of physical exercise on patients with Crohn's disease. Am J Gastroenterol. 1999;94(3):697-703
  2. Ball, E. Exercise guidelines for patients with inflammatory bowel disease. Gastroenterol Nurs. 1998;21(3):108-111.
  3. Ball, E. Exercise guidelines for patients with inflammatory bowel disease. Gastroenterol Nurs. 1998;21(3):108-111.
  4. Hart A, Kamm A. Review article: mechanisms of initiation and perpetuation of gut inflammation by stress. Aliment Pharmacol Ther. 2002;16:2017-2028.
  5. Garcia-Vega E, Fernandez-Rodriquez C. A stress management programme for Crohn's disease. Behav Res Ther. 2004;42(4):367-83.
  6. Cottone M, Rosselli M, Orlando A, Oliva L, Puleo A, Cappello M, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology. 1994;106:643-8.
  7. Fraga XF, Vergara M, Medina C, et al. Effects of smoking on the presentation and clinical course of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1997;9(7):683-7
  8. Rubin DT, Hanauer SB. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12(8):855-62
  9. Pullan RD, Rhodes J, Ganesh S, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med. 1994;330:811-815.
  10. Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126:364-371.
  11. Thomas GA, Rhodes J, Mani V, Williams GT, Newcombe RG, Russell MA, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med. 1995;332:988-92.
  12. Giese LA, Terrell L. Sexual health issues in inflammatory bowel disease. Gastroenterology Nursing. 1996;19(1): 12-17.
  13. Clinical Course of IBD by Maria Abreu
  14. Birnie GG, McLeod TI, Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut. 1981; 22(6):452-5.
  15. Narendranathan N, Sandler RS, Suchindran CM, Savitz DA. Male infertility in inflammatory bowel disease. J Clin Gastroenterol. 1989;11(4):403-6.
  16. Giese LA, Terrell L. Sexual health issues in inflammatory bowel disease. Gastroenterology Nursing. 1996;19(1): 12-17.

The next newsletter in this series by Ellen Scherl, MD, will discuss lifestyle issues and things you can do to help manage your IBD and the effect of medications. To sign up for future newsletters click here.

Back to Top

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS section in complete Prescribing Information.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms.The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for AZASAN, including BOXED WARNINGpdf

Important Safety Information about METOZOLV® ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. Take on an empty stomach up to four times daily, at least 30 minutes before eating and at bedtime.

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Complete Prescribing Information for METOZOLV ODT, including BOXED WARNING pdf

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OSMOPREP is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OSMOPREP.

OSMOPREP is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OSMOPREP be advised to adequately hydrate before, during, and after the use of OsmoPrep.

For complete Prescribing Information for OSMOPREP including BOXED WARNING.pdf

Important Safety Information about VISICOL

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. VISICOL is not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome. Use with caution in patients with impaired renal function, pre-existing electrolyte disturbances, or people taking drugs that affect electrolyte levels. VISICOL is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly observed (≥1%) adverse reactions occurring with use of VISICOL were generally transient and self-limited and included nausea, vomiting, abdominal bloating, abdominal pain, dizziness and headache.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for VISICOL, including BOXED WARNING pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.

Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter